ArticleOpen forum infectious diseases2025
Prognostic Factors of Physical Function Decline Among Middle-Aged Adults With HIV.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geriatric syndromes in women living with HIV.Current opinion in HIV and AIDS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) found small declines in physical function overall among people with HIV (PWH). However, there was substantial individual variability. The purpose of this prespecified exploratory analysis was to identify the PWH at greatest risk for physical function decline. Methods: Participant-specific annualized rates of change on annually measured chair rise rate, gait speed, the modified Short Performance Physical Battery (composite of the latter 2 plus balance time), and grip strength were estimated from linear mixed-effect models. Change in performance that was below the 20th percentile of the study population in ≥1 measure was classified as physical function decline. Associations between baseline factors and physical function decline were evaluated with log-binomial regression models. Results: Of 569 participants (81% male, 52% White), the median age (Q1-Q3) was 51 (47-55) years. Half (52%) of the participants had decline in physical function. The risk of decline was higher among females (relative risk [RR], 1.32; 95% CI, 1.12-1.55) and non-Whites (RR, 1.23; 95% CI, 1.05-1.45) and tended to increase with age (50-55 years: RR, 1.04; 95% CI, 0.86-1.26; 55+ vs 40-<50 years: RR, 1.17; 95% CI, 0.98-1.39). In models adjusted for age, sex, and race, we found greater risk of decline among those with history of depression treatment, higher body mass index (BMI), preexisting functional impairment, frailty (by index), and higher baseline high-sensitivity C-reactive protein and interleukin-6 levels. Conclusions: PWH with history of depression treatment, high BMI, or levels of inflammation and those showing early signs of functional impairment may be at higher risk of physical function decline and should be targeted for early interventions to preserve physical function with aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.